Compare Adaptive Biotechnologies Corp (ADPT) vs iShares Core High Dividend ETF (HDV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs iShares Core High Dividend ETF — how do they compare? Adaptive Biotechnologies Corp trades at $25.13 (market cap $4.04B), while iShares Core High Dividend ETF trades at $28.98. Which is the better fit depends on your goals.
| ADPT | HDV | |
|---|---|---|
Market Cap | $4.04B | — |
Sector | Health | — |
52-Week High | $25.45 | $29.14 |
52-Week Low | $12.30 | $23.64 |
Enterprise Value | $4.10B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
HDV trades at $28.92, down 0.24% on the day, with a bullish technical signal supported by moving averages. The ETF focuses on high-quality dividend stocks, offering a 3.1% yield and outperforming the S&P 500 year-to-date by 9 percentage points according to 24/7 Wall Street on July 23, 2026. Recent institutional buying includes Bay Colony Advisory Group increasing its position by 370.7% in Q2 2026.
The outlook remains positive for income investors seeking stable dividends from large-cap US companies. Key risks include interest rate sensitivity and sector concentration in defensive stocks. Institutional accumulation and strong technical momentum support continued investor interest in this dividend-focused ETF.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →
